Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio

Substance Abuse Treatment, Prevention, and Policy

Sandy Starr⁴  Jee-Seon Kim¹  Dennis McCarty²  Andy Quanbeck³  Mark Zehner³  Carol Sherbeck³  Todd Molfenter³ 

[1] University of Wisconsin–Madison, School of Education, 1057 Educational Sciences, Madison 53706, WI, USA;Oregon Health & Science University, 3181 S.W. Sam Jackson Park Rd., Portland 97239-3098, Oregon, USA;University of Wisconsin–Madison, 1513 University Avenue, Madison 53706, Wisconsin, USA;Ohio Department of Mental Health and Addiction Services (OhioMHAS), 30 East Broad Street, 8th Floor, Columbus 43215, Ohio, USA

关键词: Medication-assisted treatment;    Qualitative research;    Opioid addiction;    Buprenorphine;    Payer perspectives;   

Others  :  1172220
DOI  :  10.1186/s13011-015-0009-2

 received in 2014-11-14, accepted in 2015-03-11,  发布年份 2015

【 摘 要 】

Background

Buprenorphine is under-utilized in treating opioid addiction. Payers and providers both have substantial influence over the adoption and use of this medication to enhance recovery. Their views could provide insights into the barriers and facilitators in buprenorphine adoption.

Methods

We conducted individual interviews with 18 Ohio county Alcohol, Drug Addiction, and Mental Health Services (ADAMHS) Boards (payers) and 36 addiction treatment centers (providers) to examine barriers and facilitators to buprenorphine use. Transcripts were reviewed, coded, and qualitatively analyzed. First, we examined reasons that county boards supported buprenorphine use. A second analysis compared county boards and addiction treatment providers on perceived barriers and facilitators to buprenorphine use. The final analysis compared county boards with low and high use of buprenorphine to determine how facilitators and barriers differed between those settings.

Results

County boards (payers) promoted buprenorphine use to improve clinical care, reduce opioid overdose deaths, and prepare providers for participation in integrated models of health care delivery with primary care clinics and hospitals. Providers and payers shared many of the same perceptions of facilitators and barriers to buprenorphine use. Common facilitators identified were knowledge of buprenorphine benefits, funds allocated to purchase buprenorphine, and support from the criminal justice system. Common barriers were negative attitudes toward use of agonist pharmacotherapy, payment environment, and physician prescribing capacity. County boards with low buprenorphine use rates cited negative attitudes toward use of agonist medication as a primary barrier. County boards with high rates of buprenorphine use dedicated funds to purchase buprenorphine in spite of concerns about limited physician prescribing capacity.

Conclusions

This qualitative analysis found that attitudes toward use of medication and medication funding environment play important roles in an organization’s decision to begin buprenorphine use and that physician availability influences an organization’s ability to expand buprenorphine use over time.

Additional education, reimbursement support, and policy changes are needed to support buprenorphine adoption and use, along with a greater understanding of the roles payers, providers, and regulators play in the adoption of targeted practices.

【 授权许可】

   
2015 Molfenter et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Greenwald MK, Johanson C, Moody DE, Woods JH, Kilbourn MR, Koeppe A, Schuster CR, Zubieta J: Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003, 28(11):2000-2009.
• [2]Stoller KB, Bigelow GE, Walsh SL, Strain EC: Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 2001, 154(3):230-242.
• [3]Berglund M: A better widget? Three lessons for improving addiction treatment from a meta‐analytical study. Addiction 2005, 100(6):742-750.
• [4]Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2.
• [5]Ling W, Wesson DR: Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend 2003, 70(2):S49-S57.
• [6]Fiellin DA: The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med 2007, 1(2):62-67.
• [7]Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS Report: Trends in the Use of Methadone and Buprenorphine at Substance Abuse Treatment Facilities: 2003 to 2011. 2013: Rockville, MD.
• [8]Knudsen HK, Abraham AJ: Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders. Psychiatr Serv 2012, 63(1):19-25.
• [9]Ducharme LJ, Abraham AJ: State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy 2008, 3(1):17. BioMed Central Full Text
• [10]Molfenter T, McCarty D, Capoccia V, Gustafson D: Development of a Multilevel Framework to Increase Use of Targeted Evidence-Based Practices in Addiction Treatment Clinics. Public Health Front 2013, 2(1):11-20.
• [11]Heinrich CJ, Cummings GR: Adoption and Diffusion of Evidence‐Based Addiction Medications in Substance Abuse Treatment. Health Serv Res 2014, 49(1):127-152.
• [12]Andrews CM, D’Aunno TA, Pollack HA, Friedmann PD: Adoption of Evidence-Based Clinical Innovations: The Case of Buprenorphine Use by Opioid Treatment Programs. Med Care Res Rev 2014, 71:46-60.
• [13]Ducharme LJ, Knudsen HK, Roman PM, Johnson JA: Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. J Subst Abus Treat 2007, 32(4):321-329.
• [14]Knudsen HK, Ducharme LJ, Roman PM: Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J Subst Abus Treat 2006, 30(4):363-373.
• [15]Knudsen HK, Abraham AJ, Oser CB: Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure. Eval Program Plann 2011, 34(4):375-381.
• [16]Fuller BE, Rieckmann T, McCarty D, Smith KW, Levine H: Adoption of naltrexone to treat alcohol dependence. J Subst Abus Treat 2005, 28(3):273-280.
• [17]Koch AL, Arfken CL, Schuster CR: Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Depend 2006, 83(3):274-278.
• [18]Horgan CM, Reif S, Hodgin D, Garnick DW, Merrick EL: Availability of addiction medications in private health plans. J Subst Abus Treat 2008, 34(2):147-156.
• [19]Schroeder SA: An agenda to combat substance abuse. Health Aff 2005, 24(4):1005-1013.
• [20]Substance Abuse and Mental Health Services Administration (SAMHSA). Uniform Reporting System (URS) Output Tables. 2013 [cited 2014 September, 24]; Available from: http://www.samhsa.gov/dataoutcomes/urs/.
• [21]Centers for Disease Control (CDC): DATA2010: The Healthy People 2010 Database. National Center for Health Statistics, Atlanta, GA; 2011.
• [22]Ohio Department of Health, O.o.V.S: 2011 Ohio Drug Overdose Data: General Findings. 2011.
• [23]Sherba RT, Massatti RR, Potts L, Adhikari SB, Martt N, Starr S, Porter-Pate T: A Review of Ohio’s Treatment Capacity in Addressing the State’s Opiate Epidemic. J Drug Policy Anal 2012, 5(1):1-11.
• [24]Nicholls L, Bragaw L, Ruetsch C: Opioid dependence treatment and guidelines. J Manag Care Pharm 2010, 16(1 Suppl B):S14-21.
• [25]Heinrich CJ, Hill CJ: Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Serv Res 2008, 43(3):951-970.
• [26]Molfenter T, Kim J, Quanbeck A, Patel-Porter T, Starr S, McCarty D: Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial. Implement Sci 2013, 8(1):50. BioMed Central Full Text
• [27]Hsieh HF, Shannon SE: Three approaches to qualitative content analysis. Qual Health Res 2005, 15(9):1277-88.
• [28]ATLAS.ti, Version 6.1.16. 2011, Scientific Software Development.
• [29]Thomas DR: A general inductive approach for analyzing qualitative evaluation data. Am J Eval 2006, 27(2):237-246.
• [30]Substance Abuse and Mental Health Services Administration (SAMHSA) (2000) Drug Addiction Treatment Act of 2000. Title XXXV, Section 3502 of the Children’s Health Act of 2000. [cited 2014 November, 14]. Available at: http://buprenorphine.samhsa.gov/data.html
• [31]Massatti R, Beeghly C, Hall O, Kariisa M, Potts L: Increasing heroin overdoses in Ohio: understanding the issue. Ohio Department of Mental Health and Addiction Services, Columbus, OH; 2014.
• [32]Forrest CB, Villagra VV, Pope JE: Managing the metric vs managing the patient: the physician’s view of pay for performance. Am J Manag Care 2006, 12(2):83-5.
• [33]Higashi T, Wenger NS, Adams JL, Fung C, Roland M, McGlynn EA, Reeves D, Asch SM, Kerr E, Shelkelle PG: Relationship between number of medical conditions and quality of care. N Engl J Med 2007, 356(24):2496-2504.
• [34]Knudsen HK, DuCharme LJ, Roman PM, Link T: Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. J Subst Abus Treat 2005, 29(2):95-106.
• [35]Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ: A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010, 30(2):155-166.
• [36]Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang N, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003, 349(10):949-958.
• [37]Cunningham CO, Kunis HV, Roose RJ, Elam RT, Sohler NL: Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med 2007, 22(9):1325-9.
• [38]Hutchinson E, Catlin M, Andrilla HA, Baldwin L, Rosenblatt RA: Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med 2014, 12(2):128-33.
• [39]Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro-Donlan C, Samet JH, Alford DP: Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med 2008, 23(9):1393-8.
• [40]Knudsen HK, Abraham AJ, Roman PM: Adoption and implementation of medications in addiction treatment programs. J Addict Med 2011, 5(1):21.
• [41]Rabin BA, Brownson R, Haire-Joshua D, Kreuter MW, Weaver NL: A glossary for dissemination and implementation research in health. J Public Health Manag Pract 2008, 14(2):117-123.
• [42]Rieckmann T, Daley M, Fuller BE, Thomas CP, McCarty D: Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abus Treat 2007, 32(2):207-215.
• [43]Arfken CL, Johanson C, Menza S, Schuster R: Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. J Subst Abus Treat 2010, 39(2):96-104.
• [44]Wood E, Samet JH, Volkow ND: Physician education in addiction medicine. Jama 2013, 310(16):1673-1674.
• [45]Kennedy J, Dipzinski A, Roll J, Coyne J, Blodgett E: Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA. Drug Alcohol Depend 2011, 114(2):201-206.